{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:28:14Z","timestamp":1759177694736,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005258","name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention","doi-asserted-by":"publisher","award":["# NU65PS923666"],"award-info":[{"award-number":["# NU65PS923666"]}],"id":[{"id":"10.13039\/100005258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10461-021-03388-5","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T11:02:54Z","timestamp":1628074974000},"page":"350-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adherence to Daily Oral TDF\/FTC for PrEP in Community Health Center Populations: The Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3401-2598","authenticated-orcid":false,"given":"D. K.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Houlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"McCallister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wiener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"issue":"12","key":"3388_CR1","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973\u201383.","journal-title":"AIDS"},{"issue":"22","key":"3388_CR2","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1001\/jama.2019.2591","volume":"321","author":"R Chou","year":"2019","unstructured":"Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US preventive services task force. JAMA. 2019;321(22):2214\u201330.","journal-title":"JAMA"},{"key":"3388_CR3","unstructured":"Centers for Disease Control and Prevention, US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20132017: a clinical practice guideline. 2017:1\u201367. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2017.pdf. Accessed 1 June 2020."},{"key":"3388_CR4","unstructured":"US Preventive Services Task Force. Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis. 2019. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis. Accessed 1 June 2020."},{"issue":"9","key":"3388_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","volume":"14","author":"RM Grant","year":"2014","unstructured":"Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820\u20139.","journal-title":"Lancet Infect Dis"},{"key":"3388_CR6","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0202","author":"CA Koss","year":"2017","unstructured":"Koss CA, Bacchetti P, Hillier SL, et al. Differences in cumulative exposure and adherence to tenofovir in the Voice, iPrEx OLE, and PrEP demo studies as determined via hair concentrations. AIDS Res Hum Retrovir. 2017. https:\/\/doi.org\/10.1089\/aid.2016.0202.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"9","key":"3388_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/infdis\/jiv239","volume":"212","author":"M Gandhi","year":"2015","unstructured":"Gandhi M, Glidden DV, Liu A, et al. Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label extension: implications for pre-exposure prophylaxis adherence monitoring. J Infect Dis. 2015;212(9):1402\u20136.","journal-title":"J Infect Dis"},{"key":"3388_CR8","doi-asserted-by":"crossref","unstructured":"Liu AY, Yang Q, Huang Y, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS ONE. 2014;9(1):e83736. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24421901. Accessed 5 May 2019.","DOI":"10.1371\/journal.pone.0083736"},{"issue":"4","key":"3388_CR9","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s10461-017-1958-4","volume":"22","author":"Z Baker","year":"2018","unstructured":"Baker Z, Javanbakht M, Mierzwa S, et al. Predictors of over-reporting HIV pre-exposure prophylaxis (PrEP) adherence among young men who have sex with men (YMSM) in self-reported versus biomarker data. AIDS Behav. 2018;22(4):1174\u201383.","journal-title":"AIDS Behav"},{"issue":"1","key":"3388_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","volume":"176","author":"AY Liu","year":"2016","unstructured":"Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services. JAMA Intern Med. 2016;176(1):75\u201384.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"3388_CR11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s10461-016-1360-7","volume":"20","author":"KR Amico","year":"2016","unstructured":"Amico KR, Mehrotra M, Avelino-Silva VI, et al. Self-reported recent PrEP dosing and drug detection in an open label PrEP study. AIDS Behav. 2016;20(7):1535\u201340.","journal-title":"AIDS Behav"},{"issue":"6","key":"3388_CR12","doi-asserted-by":"publisher","first-page":"e0157742","DOI":"10.1371\/journal.pone.0157742","volume":"11","author":"MC Montgomery","year":"2016","unstructured":"Montgomery MC, Oldenburg CE, Nunn AS, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE. 2016;11(6):e0157742.","journal-title":"PLoS ONE"},{"key":"3388_CR13","doi-asserted-by":"crossref","unstructured":"Blumenthal J JS, Dube M, et al. Recent HIV risk behavior and partnership type predict PrEP adherence in men who have sex with men. Paper presented at: IDWeek 2017\/IDSA, San Diego, 4\u20138 October 2017, 2017.","DOI":"10.1093\/ofid\/ofx162.038"},{"issue":"5","key":"3388_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/QAI.0000000000000216","volume":"66","author":"KR Amico","year":"2014","unstructured":"Amico KR, Marcus JL, McMahan V, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;66(5):530.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"46","key":"3388_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.15585\/mmwr.mm6446a4","volume":"64","author":"DK Smith","year":"2015","unstructured":"Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition\u2014United States, 2015. Morb Mortal Wkly Rep. 2015;64(46):1291\u20135.","journal-title":"Morb Mortal Wkly Rep"},{"key":"3388_CR16","unstructured":"Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. FTC\/TDF (Truvada) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: 2012\u20132015, 2016. http:\/\/programme.aids2016.org\/PAGMaterial\/PPT\/5404_11614\/Mera%20TVD%20PrEP%20utilization%20IAC%202016%20FINAL.pptx. Accessed 30 July 2021"},{"key":"3388_CR17","unstructured":"Bush S, Magnuson D, Rawlings MK, Hawkins T, McCallister S, Mera-Giler R. Racial characteristics of FTC\/TDF for pre-exposure prophylaxis users in the US. Paper presented at: American Society for Microbiology, Boston, 16\u201320 June 2016, 2016."},{"key":"3388_CR18","unstructured":"Rawlings MK, Hawkins T, et al. Provider specialty and payer type trends in pre-exposure prophylaxis (PrEP) utilization (2012\u20132015). Paper presented at: HIV Research for Prevention (R4P), Chicago, 2016."},{"issue":"48","key":"3388_CR19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6848e1","volume":"68","author":"NS Harris","year":"2019","unstructured":"Harris NS, Johnson AS, Huang Y-LA, et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis\u2014United States, 2013\u20132018. Morb Mortal Wkly Rep. 2019;68(48):1117.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"4","key":"3388_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","volume":"16","author":"H Knobel","year":"2002","unstructured":"Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16(4):605\u201313.","journal-title":"AIDS"},{"issue":"3","key":"3388_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/09540120050042891","volume":"12","author":"MA Chesney","year":"2000","unstructured":"Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee & adherence working group of the outcomes committee of the adult aids clinical trials group (AACTG). AIDS Care. 2000;12(3):255\u201366.","journal-title":"AIDS Care"},{"issue":"2","key":"3388_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/aid.2012.0089","volume":"29","author":"JR Castillo-Mancilla","year":"2013","unstructured":"Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retrovir. 2013;29(2):384\u201390.","journal-title":"AIDS Res Hum Retrovir"},{"key":"3388_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-17","author":"PL Anderson","year":"2018","unstructured":"Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.01710-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3388_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10461-014-0859-z","volume":"19","author":"K Agot","year":"2015","unstructured":"Agot K, Taylor D, Corneli AL, et al. Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials. AIDS Behav. 2015;19(5):743\u201351.","journal-title":"AIDS Behav"},{"issue":"2","key":"3388_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/cid\/cix755","volume":"66","author":"CA Koss","year":"2018","unstructured":"Koss CA, Hosek SG, Bacchetti P, et al. Comparison of measures of adherence to HIV preexposure prophylaxis among adolescent and young men who have sex with men in the United States. Clin Infect Dis. 2018;66(2):213\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3388_CR26","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00216-019-02304-0","volume":"412","author":"F Pu","year":"2020","unstructured":"Pu F, Pandey S, Bushman LR, et al. Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. Anal Bioanal Chem. 2020;412(6):1243\u20139.","journal-title":"Anal Bioanal Chem"},{"issue":"9","key":"3388_CR27","doi-asserted-by":"publisher","first-page":"e1001511","DOI":"10.1371\/journal.pmed.1001511","volume":"10","author":"JE Haberer","year":"2013","unstructured":"Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.","journal-title":"PLoS Med"},{"issue":"5","key":"3388_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/QAI.0000000000000212","volume":"66","author":"C Psaros","year":"2014","unstructured":"Psaros C, Haberer JE, Katabira E, et al. An intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda. J Acquir Immune Defic Syndr. 2014;66(5):522\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"3388_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/QAI.0000000000000386","volume":"68","author":"SM Baxi","year":"2015","unstructured":"Baxi SM, Liu A, Bacchetti P, et al. Comparing the novel method of assessing PrEP adherence\/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2015;68(1):13.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"3388_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/hiv.12518","volume":"18","author":"H Koenig","year":"2017","unstructured":"Koenig H, Mounzer K, Daughtridge G, et al. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate\/emtricitabine as pre-exposure prophylaxis. HIV Med. 2017;18(6):412\u20138.","journal-title":"HIV Med"},{"key":"3388_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fphar.2019.00721","volume":"10","author":"J Blumenthal","year":"2019","unstructured":"Blumenthal J, Pasipanodya EC, Jain S, et al. Comparing self-report PrEP adherence questions to pharmacologic measures of recent and cumulative PrEP exposure. Front Pharmacol. 2019;10:721.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3388_CR32","first-page":"2093","volume":"19","author":"PA Chan","year":"2016","unstructured":"Chan PA, Mena L, Patel R, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Internat AIDS Soc. 2016;19(1):2093.","journal-title":"J Internat AIDS Soc"},{"issue":"6","key":"3388_CR33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/cid\/ciy297","volume":"67","author":"DP Serota","year":"2018","unstructured":"Serota DP, Rosenberg ES, Lockard AM, et al. Beyond the biomedical: PrEP failures in a cohort of young black men who have sex with men in Atlanta, GA. Clin Infect Dis. 2018;67(6):965\u201370.","journal-title":"Clin Infect Dis"},{"key":"3388_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11606-017-4260-2","volume":"33","author":"M Huang","year":"2018","unstructured":"Huang M, Liu W, Plomondon ME, Prochazka AV, Bessesen MT. High adherence to HIV pre-exposure prophylaxis among veterans. J Gen Intern Med. 2018;33:253\u20135.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"3388_CR35","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844\u20135.","journal-title":"JAMA"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-021-03388-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T17:25:28Z","timestamp":1643995528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-021-03388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1007\/s10461-021-03388-5","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"type":"print","value":"1090-7165"},{"type":"electronic","value":"1573-3254"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"17 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RKM and SM were employees of Gilead Sciences; LM has received research funding, honoraria as a consultant and as a member of the Gilead Sciences speaker bureau, from Gilead Sciences. All other authors declare that they have no relevant financial or nonfinancial conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The SHIPP Study received human subjects research review and approval by the CDC IRB and the IRB of the City of Philadelphia IRB and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants in the SHIPP medication adherence substudy (MAS) provided written informed consent for data and specimen collection and for publication of anonymized data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}